After Leerink Partners and H.C. Wainwright gave Biohaven Pharmaceutical Holding Co (NYSE: BHVN) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Vamil Divan reiterated a Buy rating on Biohaven Pharmaceutical Holding Co today and set a price target of $144.00. The company's shares closed last Wednesday at $123.86. According to TipRanks.com, Divan is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -3.4% and a 45.5% success rate. Divan covers the Healthcare sector, focusing on stocks such as Satsuma Pharmaceuticals, ACADIA Pharmaceuticals, and Xeris Pharmaceuticals.
https://www.tipranks.com/news/blurbs/biohaven-pharmaceutical-holding-co-bhvn-received-its-third-buy-in-a-row?utm_source=advfn.com&utm_medium=referral
Biohaven Pharmaceutical (NYSE:BHVN)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Biohaven Pharmaceutical Charts.
Biohaven Pharmaceutical (NYSE:BHVN)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Biohaven Pharmaceutical Charts.